Physician profile
Eric Heasley
NPI 1811954837
$3,279.67
in general payments reported to CMS, 2019-2025
27 companies · $674 in 2025
The $674 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $104 · 2021: $150 · 2022: $294 · 2023: $775 · 2024: $1,037 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,486 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,486.07 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,260.94 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $424.53 | 2024-2025 | Voquezna |
| Cequr Corporation | $263.14 | 2022-2023 | Cequr Simplicity |
| Smith+Nephew, INC. | $257.55 | 2023 | Grafix Pl, Stravix, Oasis |
| Janssen Pharmaceuticals, INC | $216.78 | 2019-2023 | Xarelto |
| Dexcom, INC. | $142.46 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $95.51 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $68.31 | 2022-2024 | Rybelsus, Wegovy, Ozempic |
| Novartis Pharmaceuticals Corporation | $59.13 | 2019-2021 | |
| Exact Sciences Corporation | $59.13 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.52 | 2019 | |
| Lifenet Health | $45.07 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $43.60 | 2019 | |
| Glaxosmithkline, LLC. | $37.87 | 2019-2024 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.39 | 2024-2025 | Xifaxan |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.14 | 2022-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $28.53 | 2020-2024 | |
| Amgen INC. | $24.22 | 2019 | |
| Merck Sharp & Dohme LLC | $21.25 | 2022 | |
| Allergan, INC. | $19.93 | 2019 | |
| Tactile Systems Technology INC | $18.09 | 2020 | |
| Ardelyx, INC. | $17.74 | 2025 | Ibsrela |
| Kerecis Limited | $15.45 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.33 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.83 | 2023 | |
| Horizon Therapeutics Plc | $12.44 | 2020 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Heasley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.